The FDA Has Granted Orphan Drug Designation To Can-Fite Biopharma's Namodenoson For Pancreatic Cancer
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted Orphan Drug Designation to Can-Fite Biopharma's Namodenoson for the treatment of pancreatic cancer. This designation is significant as it provides certain benefits to the company, including market exclusivity and potential tax credits.
October 09, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Can-Fite Biopharma's Namodenoson has been granted Orphan Drug Designation by the FDA for pancreatic cancer, which could lead to market exclusivity and tax credits, potentially boosting the company's market position and financials.
The Orphan Drug Designation by the FDA is a significant regulatory milestone that can provide Can-Fite Biopharma with market exclusivity for seven years upon approval, as well as tax credits for clinical testing. This can enhance the company's competitive edge and financial outlook, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100